Literature DB >> 10987299

Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1.

A S Fleisher1, M Esteller, N Harpaz, A Leytin, A Rashid, Y Xu, J Liang, O C Stine, J Yin, T T Zou, J M Abraham, D Kong, K T Wilson, S P James, J G Herman, S J Meltzer.   

Abstract

Twelve to 15% of sporadic colorectal cancers display defective DNA mismatch repair (MMR), manifested as microsatellite instability (MSI). In this group of cancers, promoter hypermethylation of the MMR gene hMLH1 is strongly associated with, and believed to be the cause of, MSI. A subset of colorectal neoplastic lesions arising in inflammatory bowel disease (IBD) is also characterized by MSI. We wished to determine whether hMLH1 hypermethylation was associated with diminished hMLH1 protein expression and MSI in IBD neoplasms. We studied 148 patients with IBD neoplasms, defined as carcinoma or dysplasia occurring in patients with ulcerative colitis or Crohn's disease. MSI was evaluated using multiplex fluorescent PCR to amplify loci D2S123, BAT-25, BAT-26, D5S346, and D17S250 in all cases. Lesions were characterized as high-frequency MSI (MSI-H) if they manifested instability at two or more loci, low-frequency MSI (MSI-L) if unstable at only one locus, or MS-stable (MSS) if showing no instability at any loci. Methylation-specific PCR was performed to determine the methylation status of the hMLH1 promoter region. hMLH1 protein expression was also evaluated by immunohistochemistry. Thirteen (9%) of 148 neoplasms arising in IBD were MSI-H, comprising 11 carcinomas and 2 dysplastic lesions. Sixteen additional lesions (11%) were MSI-L, comprising 11 carcinomas and 5 dysplastic lesions. The remaining 118 neoplasms (80%) were MSS. Six (46%) of 13 MSI-H, 1 (6%) of 16 MSI-L, and 4 (15%) of 27 MSS lesions showed hMLH1 hypermethylation (P = 0.013). Diminished hMLH1 protein expression in neoplastic cell nuclei relative to surrounding normal cell nuclei was demonstrated immunohistochemically in four of four (100%) hypermethylated lesions tested. In IBD neoplasia, hMLH1 promoter hypermethylation occurs frequently in the setting of MSI, particularly MSI-H. Furthermore, hMLH1 hypermethylation and MSI are strongly associated with diminished hMLH1 protein expression in IBD neoplasms. These findings suggest that hMLH1 hypermethylation causes defective DNA MMR in at least a subset of IBD neoplasms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987299

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis.

Authors:  H Chaib; E K Cockrell; M A Rubin; J A Macoska
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

2.  Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182.

Authors:  Mohit Sachdeva; Rebecca D Dodd; Zhiqing Huang; Carole Grenier; Yan Ma; Dina C Lev; Diana M Cardona; Susan K Murphy; David G Kirsch
Journal:  Cancer Lett       Date:  2015-08-24       Impact factor: 8.679

3.  p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease.

Authors:  Jeffrey W Nathanson; Nicole E Yadron; Jeanne Farnan; Sydney Kinnear; John Hart; David T Rubin
Journal:  Dig Dis Sci       Date:  2007-08-04       Impact factor: 3.199

Review 4.  Infection, inflammation, and gastrointestinal cancer.

Authors:  C R Boland; M G Luciani; C Gasche; A Goel
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 5.  Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

Authors:  Amosy E M'Koma; Harold L Moses; Samuel E Adunyah
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

Review 6.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

Review 7.  Ulcerative colitis-associated colorectal cancer.

Authors:  Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

8.  Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability.

Authors:  Mingyang Song; Reiko Nishihara; Kana Wu; Zhi Rong Qian; Sun A Kim; Yasutaka Sukawa; Kosuke Mima; Kentaro Inamura; Atsuhiro Masuda; Juhong Yang; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Andrew T Chan
Journal:  J Natl Cancer Inst       Date:  2015-03-25       Impact factor: 13.506

9.  Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Katherine P Liao; Isaac Kohane
Journal:  Clin Gastroenterol Hepatol       Date:  2016-02-22       Impact factor: 11.382

Review 10.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways.

Authors:  Aaron J Schetter; Niels H H Heegaard; Curtis C Harris
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.